文献速递艾滋病与性传播感染

RV144 HIV疫苗试验中未感染受试者晚期加强免疫策略的随机双盲评估

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.
PubMed 文献 · J Infect Dis · 2017-01-01

在162名HIV阴性的RV144疫苗接种者中,随机双盲评估初免后6-8年追加两剂加强免疫的安全性和免疫原性。含AIDSVAX B/E的加强组在第二周诱导的体液应答显著高于RV144末次接种后,但应答短暂且第二次加强未提高幅度。

要点

  • RV144疫苗接种者6-8年后加强AIDSVAX B/E可显著提高体液免疫应答。
  • 加强后应答短暂,第24周下降,二次加强未增加应答幅度。
  • 单独ALVAC-HIV加强组应答与安慰剂组相似。

核心结论

  • RV144疫苗接种者初免后6-8年加强AIDSVAX B/E(含或不含ALVAC-HIV)可产生高于RV144后的体液应答,但应答短暂且后续加强未增加幅度。

研究设计与样本

  • 随机安慰剂对照双盲研究,纳入162名HIV阴性RV144疫苗受试者,初免后6-8年于第0和24周加强,分3组分别接种ALVAC-HIV+AIDSVAX B/E、AIDSVAX B/E、ALVAC-HIV或安慰剂。

主要发现

  • 疫苗耐受良好。
  • 第1和2组第2周血浆IgG、IgA和中和抗体应答均显著高于RV144末次接种后2周。
  • 针对gp70V1V2 92TH023的IgG滴度较RV144末次接种后2周增加14倍(14069 vs 999;P < .001)。
  • 第1和2组间无显著差异,第3组与安慰剂组相似。
  • 第1和2组应答至第24周下降,第二次接种可加强但幅度低于第2周。

临床怎么用

  • 对于曾接种RV144方案者,晚期加强AIDSVAX B/E可短暂提升体液免疫,但需评估加强时机与持久性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The RV144 ALVAC-HIV prime, AIDSVAX B/E boost afforded 60% efficacy against human immunodeficiency virus (HIV) acquisition at 1 year, waning to 31.2% after 3.5 years. We hypothesized that additional vaccinations might augment immune correlates of protection. METHODS: In a randomized placebo-controlled double-blind study of 162 HIV-negative RV144 vaccine recipients, we evaluated 2 additional boosts, given 6-8 years since RV144 vaccination, for safety and immunogenicity, at weeks 0 and 24. Study groups 1-3 received ALVAC-HIV+AIDSVAX B/E, AIDSVAX B/E, and ALVAC-HIV, respectively, or placebo. RESULTS: Vaccines were well tolerated. For groups 1 and 2, plasma immunoglobulin (Ig) G, IgA, and neutralizing antibody responses at week 2 were all significantly higher than 2 weeks after the last RV144 vaccination. IgG titers against glycoprotein (gp) 70V1V2 92TH023 increased 14-fold compared with 2 weeks after the last RV144 vaccination (14069 vs 999; P < .001). Groups 1 and 2 did not differ significantly from each other, whereas group 3 was similar to placebo recipients. Responses in groups 1 and 2 declined by week 24 but were boosted by the second vaccination, albeit at lower magnitude than for week 2. CONCLUSIONS: In RV144 vaccinees, AIDSVAX B/E with or without ALVAC-HIV 6-8 years after initial vaccination generated higher humoral responses than after RV144, but these responses were short-lived, and their magnitude did not increase with subsequent boost. CLINICAL TRIALS REGISTRATION: NCT01435135.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Rerks-Ngarm S, Pitisuttithum P, Excler JL, et al. Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. J Infect Dis. 2017. PMID: 28329190. doi:10.1093/infdis/jix099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。